Development

Susana Saldanha, PharmD, is formulation development scientist at Hovione.

Beatriz Fernandes, MSc, is a formulation development scientist at Hovione

João Ventura, PhD, is director of Technology Development and Licensing at Hovione Technology.

Articles

Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.

Spray Drying as an Enabling Technology for Inhalation Drug Delivery

Editor of Pharmaceutical Technology Europe

Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.

Moving Beyond Particle Size Control

Vectura will support the product from Phase I through to commercial launch. 



Vectura and Monash University to Develop Inhaled Oxytocin for the Prevention of Postpartum Hemorrhage

Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.

Key Considerations When Repositioning a Known Drug for Inhalation Therapy

The Ventofor Combi Fix will be brought into the Turkish market via Bilim’s development program, while the PowdAir Plus DPI is manufactured and commercialized by H&T Presspart under a patent license from Hovione.

Bilim, H&T Presspart, and Hovione Partner to Bring Asthma Product to the Turkish Market

Particle engineering is a useful tool to manipulate API particles into a form that is manufacturable and deliverable to the patient.

A Great Manipulation: The Value of Engineering Particle Properties

Kindeva Drug Delivery plans capital investment and jobs growth.

Former 3M Drug Delivery Systems Launches as Kindeva Drug Delivery

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Delivering the Goods

Synairgen, a respiratory drug discovery and development company, has announced that it has received expedited approvals to conduct a trial of its inhaled formulation of interferon-beta-1a, SNG001, in COVID-19 patients.


UK Company Starts Trials of Inhaled Formulation for COVID-19

Perrigo will be producing a limited amount of the generic inhaler medication but will accelerate production to meet future demands in collaboration with Catalent. 

Formulation and Drug Delivery, Inhalation Drugs